The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).
short stature children aged 2 years or more
children with GHD,TS, CRF, SGA or ISS
written informed consent from the person, person's parent or legal guardian
None
children with GHD, TS, CRF, SGA and ISS
Cohort
Other
Not listed
Safety measure : adverse event
effectiveness measure : difference in target height and final height
effectiveness : difference in height velocity between Baseline and every year
effectiveness measure : difference in height SDS for CA between baseline and every 6 months
